uniQure Announces Type A Meeting Scheduled with FDA
Rhea-AI Summary
uniQure (NASDAQ: QURE) announced a Type A meeting with the FDA to discuss the Biologics License Application (BLA) data package seeking accelerated approval for AMT-130, its investigational gene therapy for Huntington's disease. The company said it expects to provide a regulatory update after receipt of official meeting minutes and emphasized continued collaboration with the FDA and commitment to patient access.
This meeting represents a formal regulatory engagement on the pathway to potential accelerated approval but does not guarantee a regulatory decision.
Positive
- Type A FDA meeting scheduled to discuss BLA for AMT-130
- Company commits to continued FDA collaboration and patient access
Negative
- No FDA decision yet; outcome depends on meeting and minutes
- Accelerated approval remains a possibility, not a confirmed result
News Market Reaction – QURE
On the day this news was published, QURE gained 9.37%, reflecting a notable positive market reaction. Argus tracked a peak move of +18.7% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $124M to the company's valuation, bringing the market cap to $1.44B at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
QURE was up 0.3% pre-news while key peers showed mixed moves: several declined (e.g., EYPT -2.4%, ABUS -3.33%, TSHA -1.15%, UPB -0.61%) and one rose (OCS +1.8%). No peers appeared in the momentum scanner and there were no same-day peer headlines, pointing to a stock-specific setup rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 04 | Regulatory update | Negative | -9.4% | Final FDA minutes signaled Phase I/II data unlikely to support BLA. |
| Nov 10 | Earnings & clinical | Negative | -5.9% | Strong AMT-130 data but wider losses and added FDA uncertainty. |
| Nov 06 | Earnings date set | Neutral | +5.6% | Announcement of upcoming Q3 2025 results and conference call. |
| Nov 03 | Regulatory update | Negative | -49.3% | FDA no longer viewing external-control Phase I/II data as adequate. |
| Sep 29 | Equity offering | Neutral | +9.4% | Closing of upsized public equity offering and full underwriter option. |
Recent QURE news around AMT-130 regulatory interactions and financing events often aligned with sizable price moves, with notably sharp declines on regulatory setbacks and gains on financing and routine corporate updates.
Over the last few months, QURE’s trajectory has been driven largely by AMT-130 regulatory updates and financing. On Nov 3, 2025 and Dec 4, 2025, FDA feedback created uncertainty about using Phase I/II external-control data as primary BLA evidence, with 24-hour moves of -49.34% and -9.38%. Q3 results on Nov 10, 2025 combined strong AMT-130 efficacy data with wider losses and regulatory questions, and the stock fell 5.9%. By contrast, an upsized equity offering closing on Sep 29, 2025 saw a 9.37% gain, and the Nov 6, 2025 earnings-date announcement saw a 5.56% rise.
Market Pulse Summary
The stock moved +9.4% in the session following this news. A strong positive reaction aligns with the market’s past sensitivity to AMT-130 regulatory milestones, where prior FDA communications drove moves of up to -49.34% in a single day. A scheduled Type A meeting about the BLA data package could be viewed as progress after earlier uncertainty. However, prior equity financing and insider sales underscore capital and governance dynamics that traders often reassess once initial enthusiasm fades.
Key Terms
type A meeting regulatory
u.s. food and drug administration (fda) regulatory
biologics license application (bla) regulatory
accelerated approval regulatory
investigational gene therapy medical
AI-generated analysis. Not financial advice.
LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the Biologics License Application (BLA) data package to support accelerated approval of AMT-130, the Company’s investigational gene therapy for the treatment of Huntington’s disease.
“We look forward to a constructive discussion with the FDA as we work toward a timely resolution regarding an accelerated approval pathway for AMT-130,” said Matt Kapusta, chief executive officer at uniQure. “The Huntington’s disease community, including patients and clinicians, has emphasized the profound unmet medical need and the importance of timely access to potentially disease-modifying therapies such as AMT-130. We remain deeply committed to patient access while continuing to collaborate closely with the FDA.”
The Company expects to provide a regulatory update after the receipt of official meeting minutes.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington’s disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases. www.uniQure.com
uniQure Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “establish,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would” and similar expressions and the negatives of those terms. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management as of the date of this press release. Examples of these forward-looking statements include, but are not limited to, statements concerning: the Company’s plans to have a Type A meeting with the FDA and work toward a timely resolution regarding an accelerated approval pathway for AMT-130; AMT-130 as a potentially disease-modifying therapy; and the Company’s plans to provide a regulatory update after receipt of official meeting minutes from the scheduled Type A meeting. The Company’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons. These risks and uncertainties include, among others: risks related to the Company’s Phase I/ll clinical trials of AMT-130, including the risk that such trials will be unable to demonstrate data sufficient to support further clinical development or regulatory approval; the risk that the FDA ultimately concludes that such trials are not adequate and well-controlled to provide the primary evidence to support a BLA; the risk that more patient data become available that results in a different interpretation then the one derived from the topline data; risks related to the Company’s interactions with regulatory authorities, which may affect the initiation, timing and progress of clinical trials and pathways to regulatory approval; whether the measurements that the Company is evaluating are viewed as robust and sensitive measurements of disease progression; whether RMAT designation, Breakthrough Therapy designation, or any accelerated pathway, if granted, will lead to regulatory approval; the Company’s ability to conduct and fund a Phase III or confirmatory study for AMT-130 if needed; the Company’s ability to continue to build and maintain the infrastructure and personnel needed to achieve its goals; the Company’s effectiveness in managing current and future clinical trials and regulatory processes; the Company’s ability to demonstrate the therapeutic benefits of its gene therapy candidates in clinical trials; the continued development and acceptance of gene therapies; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s ability to fund its operations and to raise additional capital as needed and on acceptable terms. These risks and uncertainties are more fully described under the heading “Risk Factors” in the Company’s periodic filings with the U.S. Securities & Exchange Commission (SEC), including its Annual Report on Form 10-K filed with the SEC on February 27, 2025, its Quarterly Reports on Form 10-Q filed with the SEC on May 9, 2025, July 29, 2025, and November 10, 2025 and in other filings that the Company makes with the SEC from time to time. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements and, except as required by law, the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.
| uniQure Contacts: FOR INVESTORS: Chiara Russo Direct: 781-491-4371 Mobile: 617-306-9137 c.russo@uniQure.com | FOR MEDIA: Tom Malone Direct: 339-970-7558 Mobile:339-223-8541 t.malone@uniQure.com |
FAQ
What did uniQure (QURE) announce on January 9, 2026 about AMT-130?
Does the Type A meeting mean AMT-130 has FDA approval for Huntington's disease?
When will investors learn the FDA meeting outcome for QURE's AMT-130?
How does the uniQure announcement affect patient access to AMT-130?
What is the regulatory focus of the FDA meeting for QURE's AMT-130?
